Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Addison’s Disease Market Be Worth By 2029?

The market size for Addison’s disease has seen robust expansion over the past few years. The market is projected to rise from $2.05 billion in 2024 to $2.24 billion in 2025, featuring a compound annual growth rate (CAGR) of 9.7%. The growth observed since the historic period can be attributed to several factors, including global surge in Addison’s disease incidences, heightened consciousness about adrenal insufficiency, increment in healthcare spending, rising occurrences of autoimmune diseases, and an expanding elderly population.

Expected to undergo significant growth in the forthcoming years, the Addison’s disease market size is predicted to reach $3.24 billion by 2029, with a compound annual growth rate (CAGR) of 9.6%. This growth during the forecast period is associated with an increased need for advanced treatments, greater emphasis on early detection, an upward trend in cases of congenital adrenal hyperplasia, the expansion of telemedicine services, and a rise in adrenal tuberculosis instances. The forecast period is also expected to see key trends such as advancements in lab test procedures, developments in hormone replacement therapies, progress in imaging technologies, the creation of long-lasting injectable formulas, and the incorporation of artificial intelligence into diagnostic tools.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21084&type=smp

What Market Forces Are Contributing To The Growth Of The Addison’s Disease Market?

The rise in incidence of autoimmune diseases is anticipated to spur the growth of the Addison’s disease market. Autoimmune diseases develop when the body’s immune system mistakenly attacks healthy tissues, causing inflammation and damage. Factors such as genetic predispositions, environmental pollutants, changes in diet, and lifestyle factors such as stress and insufficient physical activity are all contributing to the rise in cases of autoimmune diseases. The increasing incidence of autoimmune diseases raises the probability of co-existing Addison’s disease, as many patients gradually develop other autoimmune disorders. An instance highlighting this is a report by Versorgungsatlas.de, a Germany-based organization, in November 2024. The report stated that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, equating to a raw prevalence rate of 8.61%, which surpasses earlier estimates of 3% to 9%. Consequently, the rising incidence of autoimmune diseases is fueling the expansion of the Addison’s disease market.

Which Segments Define The Structure Of The Addison’s Disease Market?

The addison’s diseasemarket covered in this report is segmented –

1) By Type: Primary Adrenal Insufficiency; Secondary Adrenal Insufficiency; Tertiary Adrenal Insufficiency

2) By Drug Class: Oral Corticosteroid; Hydrocortisone; Fludrocortisone; Corticosteroid Injections

3) By Diagnosis: Laboratory Testing; Imaging Testing

4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users

Subsegments:

1) By Primary Adrenal Insufficiency: Autoimmune Addison’s Disease; Infectious Addison’s Disease; Other causes of primary adrenal insufficiency

2) By Secondary Adrenal Insufficiency: Pituitary gland dysfunction; Hypothalamic dysfunction

3) By Tertiary Adrenal Insufficiency: Hypothalamic or pituitary suppression due to long-term steroid use; Other causes of tertiary adrenal insufficiency

Which Disruptive Trends Are Driving Change Across The Addison’s Disease Market?

Leading firms in the addison’s disease industry are turning their focus towards innovative procedures such as regenerative treatments to improve patient prognosis and potentially minimize the persistent need for hormone replacement therapies by invigorating the body’s inherent adrenal function. Regenerative treatments represent medicinal strategies that aim to restore human cells, tissues, or organs to their normal condition and aid in healing in scenarios of injury, disease, or decay. For instance, Eton Pharmaceuticals, Inc., a public pharmaceutical firm which is headquartered in the US and concentrates on the creation and commercialization of ground-breaking treatments for uncommon diseases, confirmed in July 2024 that its New Drug Application (NDA) for ET-400, a unique formulation of hydrocortisone oral solution, had been validated by the FDA. Compared to other formulations which may need refrigeration, ET-400 is simpler to keep and transfer. The liquid format meets the requirements of younger patients who may find it hard to swallow traditional tablets and provides precise dosage controls.

Which Firms Are Making The Biggest Impact In The Addison’s Disease Market?

Major companies operating in the addison’s disease market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz, Ipsen S.A., Neurocrine Biosciences Inc., Recipharm AB, Accord Healthcare, Eton Pharmaceuticals, DuoCort Pharma, Diurnal Group plc, Roxane Laboratories Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/addisons-disease-global-market-report

Which Region Is Forecasted To Lead The Addison’s Disease Market In The Coming Years?

North America was the largest region in the addison’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the addison’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21084&type=smp

Browse Through More Reports Similar to the Global Addison’s Disease Market 2025, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model